138 related articles for article (PubMed ID: 6387059)
1. A phase III clinical trial comparing the combination cyclophosphamide, adriamycin, cisplatin with cyclophosphamide, 5-fluorouracil, prednisone in patients with advanced breast cancer.
Creagan ET; Green SJ; Ahmann DL; Ingle JN; Edmonson JH; Marschke RF
J Clin Oncol; 1984 Nov; 2(11):1260-5. PubMed ID: 6387059
[TBL] [Abstract][Full Text] [Related]
2. CAP (cyclophosphamide, adriamycin, platinum) vs CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisolone) combination chemotherapy in untreated metastatic breast cancer. A preliminary report of a controlled clinical study.
Kolarić K; Roth A; Vukas D; Cervek J
Cancer Chemother Pharmacol; 1984; 13(2):142-4. PubMed ID: 6380789
[TBL] [Abstract][Full Text] [Related]
3. Randomized clinical trial of cyclophosphamide, 5-FU, and prednisone with or without tamoxifen in postmenopausal women with advanced breast cancer.
Krook JE; Ingle JN; Green SJ; Bowman WD; Everson LK; Windschitl HE; Marschke RF; Laurie JA; Cullinan SA; Pfeifle DM
Cancer Treat Rep; 1985 Apr; 69(4):355-61. PubMed ID: 3888386
[TBL] [Abstract][Full Text] [Related]
4. [Clinical study of comparison of CAF regimen and TP regimen in treatment of advanced breast cancer].
Lin XG; Xie DR; Yao HR; Li ZH; Jiang ZM; Liu TH
Ai Zheng; 2003 Apr; 22(4):411-4. PubMed ID: 12704001
[TBL] [Abstract][Full Text] [Related]
5. Combination of cyclophosphamide, adriamycin and platinum (CAP) versus 5-fluorouracil, adriamycin and cyclophosphamide (FAC) as primary treatment in metastatic breast cancer: results of a prospective randomized study.
Kolarić K; Vukas D; Potrebica V
Tumori; 1989 Apr; 75(2):132-6. PubMed ID: 2741218
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial of cyclophosphamide, doxorubicin, and prednisone versus cyclophosphamide, 5-fluorouracil, and prednisone in patients with metastatic breast cancer.
Ahmann DL; Schaid DJ; Ingle JN; Bisel HF; Schutt AJ; Buckner JC; Long HJ; Rubin J
Am J Clin Oncol; 1991 Jun; 14(3):179-83. PubMed ID: 2031502
[TBL] [Abstract][Full Text] [Related]
7. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial.
; Ambrosini G; Balli M; Garusi G; Demicheli R; Jirillo A; Bonciarelli G; Bruscagnin G; Fila G; Bumma C; Lacroix F; Buzzi F; Di Costanzo F; Padalino D; Brugia M; Calabresi F; Natali M; Cartei G; Chiesa G; Blasina B; Ciambellotti E; Moro G; D'Aquino S; Altavilla G; Adamo V; De Maria D; Falchi AM; Bertoncelli P; Farris A; Fiorentino M; Fornasiero A; Fosser V; Daniele O; Foggi CM; Speranza GB; Sartori S; Camilluzzi E; Gallo L; Poggio R; Secondo V; Gambi A; Grignani F; Capodicasa E; Lopez M; Papaldo P; Di Lauro L; Vici P; Marenco G; Folco U; Bonanni F; Marsilio P; Palazzotto G; Di Carlo A; Cusimano MP; Pastorino G; Puccetti C; Giusto M; Rausa L; Gebbia N; Palmeri S; D'Alessandro N; Saccani F; Becchi G; Schieppati G; Spinelli I; Tagliagambe A; Tonato M; Minotti V; Ardia A; Viaro D; De Micheli P; Zingali G; Sacchetti G; Intini C
J Clin Oncol; 1988 Jun; 6(6):976-82. PubMed ID: 2897433
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effect of combination of cyclophosphamide, adriamycin and platinum (CAP) versus cyclophosphamide, adriamycin and 5-fluorouracil (CAF) in metastatic breast cancer.
Tzekova V; Velikova M; Koynov K; Micheva D; Donchev T
Neoplasma; 1991; 38(6):603-7. PubMed ID: 1766485
[TBL] [Abstract][Full Text] [Related]
9. cis-platinum-based alternating non-cross-resistant chemotherapy as a first-line treatment in metastatic breast cancer. A phase II study.
Kolarić K; Tomek R
Tumori; 1990 Oct; 76(5):472-5. PubMed ID: 2256193
[TBL] [Abstract][Full Text] [Related]
10. Aggressive doxorubicin-containing regimen (prednisone, methotrexate, 5-FU, doxorubicin, and cyclophosphamide; PM-FAC) in disseminated estrogen receptor-negative breast cancer.
Mortimer J; Livingston RB; Hardesty IJ; Groppe CW; Purvis JD; Gupta M; Flournoy N
Cancer Treat Rep; 1984; 68(7-8):1017-8. PubMed ID: 6744334
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.
Aisner J; Cirrincione C; Perloff M; Perry M; Budman D; Abrams J; Panasci L; Muss H; Citron M; Holland J
J Clin Oncol; 1995 Jun; 13(6):1443-52. PubMed ID: 7751891
[TBL] [Abstract][Full Text] [Related]
12. Treatment of advanced breast cancer with cyclophosphamide, 5-fluorouracil, and prednisone with and without methanol-extracted residue of BCG.
Britell JC; Ahmann DL; Bisel HF; Frytak S; Ingle JN; Rubin J; O'Fallon JR
Cancer Clin Trials; 1979; 2(4):345-50. PubMed ID: 394870
[TBL] [Abstract][Full Text] [Related]
13. Cyclophosphamide, adriamycin, and cis-platinum (CAP) in metastatic and locally advanced breast cancer.
Verusio C; Bajetta E; Ferrari L; Bartoli C; Valagussa P; Bonadonna G
Am J Clin Oncol; 1988 Aug; 11(4):435-9. PubMed ID: 3407621
[TBL] [Abstract][Full Text] [Related]
14. A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer: a Southeastern Cancer Study Group project.
Smalley RV; Carpenter J; Bartolucci A; Vogel C; Krauss S
Cancer; 1977 Aug; 40(2):625-32. PubMed ID: 329975
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
[TBL] [Abstract][Full Text] [Related]
16. A randomized study of intensive versus moderate chemotherapy programs in metastatic breast cancer.
Rosner D; Nemoto T; Lane WW
Cancer; 1987 Mar; 59(5):874-83. PubMed ID: 3815266
[TBL] [Abstract][Full Text] [Related]
17. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.
J Clin Oncol; 1988 Apr; 6(4):679-88. PubMed ID: 2895801
[TBL] [Abstract][Full Text] [Related]
18. High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer.
Bosnjak SM; Nesković-Konstantinović ZB; Radulović SS; Susnjar S; Mitrovi LB
J Chemother; 2000 Oct; 12(5):446-53. PubMed ID: 11128567
[TBL] [Abstract][Full Text] [Related]
19. Combination chemotherapy in advanced breast cancer.: a randomized trial comparing a three-vs a five-drug program.
Muss HB; White DR; Cooper MR; Richards F; Spurr CL
Arch Intern Med; 1977 Dec; 137(12):1711-4. PubMed ID: 337916
[TBL] [Abstract][Full Text] [Related]
20. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma.
Bennett JM; Muss HB; Doroshow JH; Wolff S; Krementz ET; Cartwright K; Dukart G; Reisman A; Schoch I
J Clin Oncol; 1988 Oct; 6(10):1611-20. PubMed ID: 3049953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
